Johnson & Johnson (JNJ)
NYSE: JNJ · Real-Time Price · USD
259.91
+5.12 (2.01%)
Oct 7, 2026, 12:49 PM EDT - Market open
Johnson & Johnson Revenue
Johnson & Johnson had revenue of $25.31B in the quarter ending June 30, 2026, with 6.60% growth. This brings the company's revenue in the last twelve months to $97.93B, up 8.06% year-over-year. In the year 2025, Johnson & Johnson had annual revenue of $94.19B with 6.05% growth. That makes Johnson & Johnson the world's #86 largest public company by revenue and #40 in the United States.
Revenue (ttm)
$97.93B
Revenue Growth
+8.06%
P/S Ratio
6.27
Revenue / Employee
$708,603
Employees
138,200
Market Cap
626.34B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 94.19B | 5.37B | 6.05% |
| Dec 31, 2024 | 88.82B | 3.66B | 4.30% |
| Dec 31, 2023 | 85.16B | 5.17B | 6.46% |
| Jan 1, 2023 | 79.99B | 1.25B | 1.59% |
| Jan 2, 2022 | 78.74B | -3.84B | -4.65% |
| Jan 3, 2021 | 82.58B | 525.00M | 0.64% |
| Dec 31, 2019 | 82.06B | 478.00M | 0.59% |
| Dec 31, 2018 | 81.58B | 5.13B | 6.71% |
| Dec 31, 2017 | 76.45B | 4.56B | 6.34% |
| Jan 1, 2017 | 71.89B | 1.82B | 2.59% |
| Jan 3, 2016 | 70.07B | -4.26B | -5.73% |
| Dec 31, 2014 | 74.33B | 3.02B | 4.23% |
| Dec 31, 2013 | 71.31B | 4.09B | 6.08% |
| Dec 30, 2012 | 67.22B | 2.19B | 3.37% |
| Jan 1, 2012 | 65.03B | 3.44B | 5.59% |
| Jan 2, 2011 | 61.59B | -310.00M | -0.50% |
| Jan 3, 2010 | 61.90B | -1.85B | -2.90% |
| Dec 28, 2008 | 63.75B | 2.65B | 4.34% |
| Dec 30, 2007 | 61.10B | 7.77B | 14.57% |
| Dec 31, 2006 | 53.32B | 2.81B | 5.56% |
| Jan 1, 2006 | 50.51B | 3.17B | 6.69% |
| Jan 2, 2005 | 47.35B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Eli Lilly and Company | 79.67B |
| Merck & Co. | 66.57B |
| AbbVie | 64.39B |
| Pfizer | 63.70B |
| AstraZeneca | 61.37B |
| Novartis AG | 56.69B |
| Sanofi | 55.89B |
| Novo Nordisk | 50.34B |
JNJ News
- 1 day ago - Johnson & Johnson price target raised to $290 from $287 at RBC Capital - TheFly
- 2 days ago - Johnson & Johnson price target raised to $303 from $298 at Citi - TheFly
- 5 days ago - Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study - TheFly
- 5 days ago - Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy - PRNewsWire
- 6 days ago - New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause - Business Wire
- 8 days ago - Johnson & Johnson’s Imaavy shows efficacy in gMG Phase 2/3 trial - TheFly
- 8 days ago - Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) - PRNewsWire
- 8 days ago - Johnson & Johnson price target raised to $285 from $270 at JPMorgan - TheFly